UNLABELLED: The most common site of metastasis for breast cancer is bone. Quantitative (18)F-fluoride PET can estimate the kinetics of fluoride incorporation into bone as a measure of fluoride transport, bone formation, and turnover. The purpose of this analysis was to evaluate the accuracy and precision of (18)F-fluoride model parameter estimates for characterizing regional kinetics in metastases and normal bone in breast cancer patients. METHODS: Twenty metastatic breast cancer patients underwent dynamic (18)F-fluoride PET. Mean activity concentrations were measured from serial blood samples and regions of interest placed over bone metastases, normal vertebrae, and cardiac blood pools. This study examined parameter identifiability, model sensitivity, error, and accuracy using parametric values from the patient cohort. RESULTS: Representative time-activity curves and model parameter ranges were obtained from the patient cohort. Model behavior analyses of these data indicated (18)F-fluoride transport and flux (K(1) and Ki, respectively) into metastatic and normal osseous tissue could be independently estimated with a reasonable bias of 9% or less and reasonable precision (coefficients of variation <or= 16%). Average (18)F-fluoride transport and flux into metastases from 20 patients (K(1) = 0.17 +/- 0.08 mL x cm(-3) x min(-1) and Ki = 0.10 +/- 0.05 mL x cm(-3) x min(-1)) were both significantly higher than for normal bone (K(1) = 0.09 +/- 0.03 mL x cm(-3) x min(-1) and Ki = 0.05 +/- 0.02 mL x cm(-3) x min(-1), P < 0.001). CONCLUSION: Fluoride transport and flux can be accurately and independently estimated for bone metastases and normal vertebrae. Reasonable bias and precision for estimates of K(1) and Ki from simulations and significant differences in values from patient modeling results in metastases and normal bone suggest that (18)F-fluoride PET images may be useful for assessing changes in bone turnover in response to therapy. Future studies will examine the correlation of parameters to biologic features of bone metastases and to response to therapy.
UNLABELLED: The most common site of metastasis for breast cancer is bone. Quantitative (18)F-fluoride PET can estimate the kinetics of fluoride incorporation into bone as a measure of fluoride transport, bone formation, and turnover. The purpose of this analysis was to evaluate the accuracy and precision of (18)F-fluoride model parameter estimates for characterizing regional kinetics in metastases and normal bone in breast cancerpatients. METHODS: Twenty metastatic breast cancerpatients underwent dynamic (18)F-fluoride PET. Mean activity concentrations were measured from serial blood samples and regions of interest placed over bone metastases, normal vertebrae, and cardiac blood pools. This study examined parameter identifiability, model sensitivity, error, and accuracy using parametric values from the patient cohort. RESULTS: Representative time-activity curves and model parameter ranges were obtained from the patient cohort. Model behavior analyses of these data indicated (18)F-fluoride transport and flux (K(1) and Ki, respectively) into metastatic and normal osseous tissue could be independently estimated with a reasonable bias of 9% or less and reasonable precision (coefficients of variation <or= 16%). Average (18)F-fluoride transport and flux into metastases from 20 patients (K(1) = 0.17 +/- 0.08 mL x cm(-3) x min(-1) and Ki = 0.10 +/- 0.05 mL x cm(-3) x min(-1)) were both significantly higher than for normal bone (K(1) = 0.09 +/- 0.03 mL x cm(-3) x min(-1) and Ki = 0.05 +/- 0.02 mL x cm(-3) x min(-1), P < 0.001). CONCLUSION:Fluoride transport and flux can be accurately and independently estimated for bone metastases and normal vertebrae. Reasonable bias and precision for estimates of K(1) and Ki from simulations and significant differences in values from patient modeling results in metastases and normal bone suggest that (18)F-fluoride PET images may be useful for assessing changes in bone turnover in response to therapy. Future studies will examine the correlation of parameters to biologic features of bone metastases and to response to therapy.
Authors: R A Hawkins; Y Choi; S C Huang; C K Hoh; M Dahlbom; C Schiepers; N Satyamurthy; J R Barrio; M E Phelps Journal: J Nucl Med Date: 1992-05 Impact factor: 10.057
Authors: M Petrén-Mallmin; I Andréasson; O Ljunggren; H Ahlström; J Bergh; G Antoni; B Långström; M Bergström Journal: Skeletal Radiol Date: 1998-02 Impact factor: 2.199
Authors: M Piert; T T Zittel; H J Machulla; G A Becker; M Jahn; G Maier; R Bares; H D Becker Journal: J Bone Miner Res Date: 1998-08 Impact factor: 6.741
Authors: Tsuyoshi Hamaoka; John E Madewell; Donald A Podoloff; Gabriel N Hortobagyi; Naoto T Ueno Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: C Messa; W G Goodman; C K Hoh; Y Choi; A R Nissenson; I B Salusky; M E Phelps; R A Hawkins Journal: J Clin Endocrinol Metab Date: 1993-10 Impact factor: 5.958
Authors: Joanne M Wells; David A Mankoff; Mark Muzi; Finbarr O'Sullivan; Janet F Eary; Alexander M Spence; Kenneth A Krohn Journal: Mol Imaging Date: 2002-07 Impact factor: 4.488
Authors: Evan Y Yu; Fenghai Duan; Mark Muzi; Xuan Deng; Bennett B Chin; Joshi J Alumkal; Mary-Ellen Taplin; Jina M Taub; Ben Herman; Celestia S Higano; Robert K Doot; Donna Hartfeil; Philip G Febbo; David A Mankoff Journal: J Nucl Med Date: 2015-01-29 Impact factor: 10.057
Authors: Urban Simoncic; Scott Perlman; Glenn Liu; Mary Jane Staab; Jane Elizabeth Straus; Robert Jeraj Journal: Clin Genitourin Cancer Date: 2014-07-15 Impact factor: 2.872
Authors: Yang Zuo; Souvik Sarkar; Michael T Corwin; Kristin Olson; Ramsey D Badawi; Guobao Wang Journal: Phys Med Biol Date: 2019-09-05 Impact factor: 3.609
Authors: Alejandro Sanchez-Crespo; Frederik Christiansson; Charlotte Karlsson Thur; Henrik Lundblad; Anders Sundin Journal: Eur J Nucl Med Mol Imaging Date: 2016-07-23 Impact factor: 9.236